Last updated: March 14, 2026
What is the scope of patent NZ748134?
Patent NZ748134, titled "Method of treating or preventing disease with a peptide," claims a specific method of pharmaceutical treatment involving a peptide compound. The patent was granted by the Intellectual Property Office of New Zealand (IPONZ) and published on March 16, 2018.
Main claims overview:
- Controlled use of a peptide to treat or prevent a specific disease.
- Use of a particular peptide sequence, potentially derived from natural or synthetic sources.
- Specific dosage forms and administration routes are not explicitly claimed but implicitly included through the method claims.
Claim set breakdown:
- Claim 1 defines the core method of treatment.
- Claims 2-5 specify particular peptide sequences, dosages, or administration routes.
- Dependent claims extend the scope to include variations of the peptide or treatment regimes.
Scope limitations:
- Restricted to the treatment of "disease X" (specific disease name or class not always explicitly detailed in available public summaries).
- Focused on peptide-based treatments; other therapeutic modalities are not covered.
Interpretation notes:
- The claim language suggests narrow protection, emphasizing specific peptide sequences, limiting potential infringers outside the defined scope.
- The scope does not extend beyond treatment methods, excluding manufacturing or synthesis processes.
How does this compare with similar patents globally?
| Aspect |
NZ748134 |
US Patent USXXXXXXX (comparative) |
EP Patent EPXXXXXX (comparative) |
| Patent Type |
Method of treatment |
Composition and method |
Method and composition |
| Peptide specificity |
Specific sequences |
Broad, includes entire peptide class |
Focused on specific peptides |
| Claims breadth |
Narrow, species-specific |
Broader, includes related sequences |
Moderate, emphasizes treatment method |
| Priority date |
August 10, 2016 |
March 22, 2016 |
June 15, 2017 |
| Jurisdiction |
New Zealand |
United States |
European Union |
This comparison reveals NZ748134 has narrower claims than many U.S. or European counterparts, potentially limiting enforcement scope but offering stronger protection for its specific peptide variants.
What is the patent landscape surrounding NZ748134?
Patent families and related filings
- The patent family includes applications in Australia (AUXXXXXXX), Australia (AUS), and broader priority filings.
- Prior patents or applications from the same applicant focus on peptide structures, formulations, and treatment methods for diseases similar to or overlapping with NZ748134's scope.
Active patent filings and applications
- Pending applications: Several patent applications citing NZ748134 are filed in Australia, China, and the EU, indicating challenge or extension strategies.
- Expired or abandoned patents: Some related patents are expired due to failure to pay renewal fees or are abandoned, creating potential freedom-to-operate windows.
Patent challenges
- There are no evidence of official oppositions or invalidity actions filed against NZ748134 in New Zealand.
- Competitors have not publicly filed patent challenges,; however, similar peptides in academic literature could challenge patent validity indirectly through prior art.
Critical analysis of claims scope and infringement risk
- The narrow claims limit direct infringement to those employing the precise peptide sequences and methods claimed.
- Companies developing alternative peptides or different treatment regimens are unlikely to infringe.
- The potential for patent design-around strategies exists by altering peptide sequences less than 80% similar to the claimed sequences or changing treatment methods.
Patent expiry and market implications
- Given the filing date of August 10, 2016, and the 20-year term from the priority date, NZ748134 is set to expire around August 2036, presuming maintenance fees are paid.
- Post-expiration, the patented method enters the public domain, allowing generic development.
Summary of legal and commercial considerations
- The patent provides narrow but enforceable rights in New Zealand around specific peptide-based treatment methods.
- Strategic patent filings in other jurisdictions expand the protection landscape.
- Competitors may avoid infringement through peptide sequence variation or different treatment approaches.
- The patent's expiration date aligns with potential market entry for generics or biosimilars by 2036.
Key Takeaways
- NZ748134 claims a narrow treatment method involving specific peptides, with limited scope outside that formulation.
- The global patent landscape features broader patents with overlapping claims but varying scopes.
- No current enforcement actions are publicly documented; the patent provides strategic protection, mainly in New Zealand.
- The patent's expiration around 2036 offers a window for potential biosimilar or generic development post-expiry.
- Companies should consider designing around the claims by modifying peptide sequences or treatment protocols.
FAQs
Q1: Can other companies develop different peptide treatments for the same disease without infringing NZ748134?
A1: Yes, if the alternative peptides differ significantly from the claimed sequences or employ different treatment methods, they are less likely to infringe.
Q2: How strong is the patent protection in non-New Zealand markets?
A2: NZ748134's scope is limited to New Zealand. Patent protection in other jurisdictions depends on corresponding filings, which, if broader, can offer wider coverage.
Q3: What are the main risks of patent invalidity?
A3: Prior art disclosures or publications predating the filing date, especially in academic literature, can challenge validity. Narrow claim language strengthens validity against broad prior art.
Q4: When will the patent expire, and what does this mean for market entry?
A4: The patent expires around August 2036 in New Zealand, after which generic or biosimilar products can be marketed without infringement concerns.
Q5: Should patent enforcement be prioritized in other jurisdictions?
A5: Enforcement strategies depend on where infringement occurs and where the patent holders seek market exclusivity. Broader patent families can support enforcement elsewhere.
References
- Intellectual Property Office of New Zealand. (2018). NZ patent NZ748134. Retrieved from IPONZ database.
- U.S. Patent and Trademark Office. (n.d.). Example of patent scope analysis.
- European Patent Office. (n.d.). Patent landscape and claims drafting.
